Cargando…

Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma

INTRODUCTION: The identification of specific targets for treatment of ovarian cancer patients remains a challenge. The objective of this study is the analysis of oncogenic pathways in ovarian cancer and their relation with clinical outcome. METHODOLOGY: A meta-analysis of 6 gene expression datasets...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trinh, Xuan Bich, Tjalma, Wiebren A. A., Dirix, Luc Y., Vermeulen, Peter B., Peeters, Dieter J., Bachvarov, Dimcho, Plante, Marie, Berns, Els M., Helleman, Jozien, Van Laere, Steven J., van Dam, Peter A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143137/ https://www.ncbi.nlm.nih.gov/pubmed/21799864 http://dx.doi.org/10.1371/journal.pone.0022469

Ejemplares similares

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
por: Trinh, X B, et al.
Publicado: (2009)

In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment
por: van Dam, Peter A., et al.
Publicado: (2015)

The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Van Berckelaer, Christophe, et al.
Publicado: (2021)

A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer
por: Van Berckelaer, C., et al.
Publicado: (2020)

RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
por: van Dam, Peter A., et al.
Publicado: (2019)

Inhibition of RUNX2 Transcriptional Activity Blocks the Proliferation, Migration and Invasion of Epithelial Ovarian Carcinoma Cells
por: Wang, Zhi-Qiang, et al.
Publicado: (2013)

Molecular profiles to biology and pathways: a systems biology approach
por: Van Laere, Steven, et al.
Publicado: (2016)

Benchmarking and audit of breast units improves quality of care
por: van Dam, P.A., et al.
Publicado: (2013)

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy
por: Sheta, Razan, et al.
Publicado: (2020)

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
por: Vitale, Silvia R., et al.
Publicado: (2020)

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
por: Van Berckelaer, C., et al.
Publicado: (2019)

Are Costs of Robot-Assisted Surgery Warranted for Gynecological Procedures?
por: van Dam, Peter, et al.
Publicado: (2011)

Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients
por: Van der Auwera, Ilse, et al.
Publicado: (2010)

SARS-CoV-2 and cancer: Are they really partners in crime?
por: van Dam, Peter A., et al.
Publicado: (2020)

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers
por: van Schooneveld, Eleni, et al.
Publicado: (2012)

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
por: Ouellet, Véronique, et al.
Publicado: (2008)

The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy
por: Oner, Gizem, et al.
Publicado: (2023)

Mismatch repair and treatment resistance in ovarian cancer
por: Helleman, Jozien, et al.
Publicado: (2006)

Successful Pregnancies after the Treatment of a Thymic Carcinoid
por: Tjalma, Wiebren A. A.
Publicado: (2015)

Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma
por: Tjalma, Wiebren A. A.
Publicado: (2015)

Surgical management of cervical cancer by laparoscopy or laparotomy?
por: Tjalma, Wiebren A.A.
Publicado: (2018)

The vaginal bridge
por: Tjalma, Wiebren A. A.
Publicado: (2019)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

The interaction between ER and NFκB in resistance to endocrine therapy
por: Sas, Leen, et al.
Publicado: (2012)

Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
por: Oeyen, Steffi, et al.
Publicado: (2020)

Evaluation and consequences of heterogeneity in the circulating tumor cell compartment
por: Brouwer, Anja, et al.
Publicado: (2016)

Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation
por: Wang, Zhi-Qiang, et al.
Publicado: (2014)

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
por: Furrer, Daniela, et al.
Publicado: (2019)

Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth
por: Vermeulen, P B, et al.
Publicado: (2009)

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting
por: Peeters, D J E, et al.
Publicado: (2013)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Role of malignant ascites on human mesothelial cells and their gene expression profiles
por: Matte, Isabelle, et al.
Publicado: (2014)

Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype
por: Van der Auwera, I, et al.
Publicado: (2010)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques
por: Brouwer, Anja, et al.
Publicado: (2019)

Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer
por: Van der Auwera, I, et al.
Publicado: (2010)

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
por: van Jaarsveld, Marijn T. M., et al.
Publicado: (2015)

A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples
por: Marsan, Melike, et al.
Publicado: (2014)

Study Assessing the Quality of Quantification of Estrogen Receptor Protein Expression by Immunohistochemistry and Gene Expression in Breast Cancer
por: Leen, Sas, et al.
Publicado: (2014)

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
por: Dirix, Luc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3fh8o0te04d54rfcsa1vdqsk9i